

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOSTIME

Biostime International Holdings Limited

合生元國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1112)

RE-DESIGNATION OF DIRECTOR AND CHANGE OF CHIEF TECHNOLOGY OFFICER

The Board announces that Dr. Zhang has been re-designated from an executive Director to a non-executive Director with effect from 25 June 2012. Dr. Zhang also resigned his other positions in the Company, including the position as the chief technology officer of the Company, with effect from 25 June 2012.

The Board also announces that Dr. Patrice Malard has been appointed as the chief technology officer of the Company with effect from 25 June 2012.

RE-DESIGNATION OF DIRECTOR AND RESIGNATION OF CHIEF TECHNOLOGY OFFICER

The board (the “**Board**”) of directors (the “**Directors**”) of Biostime International Holdings Limited (the “**Company**”) and together with its subsidiaries, the “**Group**”) announces that Dr. Zhang Wenhui (“**Dr. Zhang**”) has been re-designated from an executive Director to a non-executive Director with effect from 25 June 2012 as Dr. Zhang would like to spend more time on his family life. Dr. Zhang also resigned his other positions in the Company, including the position as the chief technology officer of the Company, with effect from 25 June 2012.

Dr. Zhang, aged 46, has almost 16 years of experience in the industry of biotechnology. He joined the Group as the chief technology officer of Biostime, Inc. (Guangzhou) (“**Biostime Guangzhou**”), a subsidiary of the Company in October 2005, and was appointed as a general manager of the technology center of Biostime (Guangzhou) Health Products Limited, a subsidiary of the Company on 10 December 2010. Dr. Zhang was appointed as an executive Director on 12 May 2010 and was the chief technology officer and head of the Quality Assurance Department of the Company prior to his re-designation of director and resignation of his other positions in the Company.

Dr. Zhang is currently a director and a shareholder of Biostime Pharmaceuticals (China) Limited (“**Biostime Pharmaceuticals**”), a controlling shareholder of the Company, which held approximately 74.7% of the issued shares of the Company as of the date of this

announcement. Dr. Zhang was beneficially interested in 10% of Biostime Pharmaceuticals as of the date of this announcement.

Dr. Zhang has terminated his service contract as an executive Director with the Company with effect from 25 June 2012 and entered into a new letter of appointment (“**Appointment Letter**”) as a non-executive director with the Company for an initial term of three years commencing on 25 June 2012 until terminated by not less than one-month’s notice in writing served by either party on the other. Dr. Zhang will not receive any director’s fee during his appointment as a non-executive Director. Dr. Zhang is subject to retirement by rotation and re-election at least once every three years in accordance with the articles of association of the Company.

On 12 July 2010, Dr. Zhang had accepted a share option to subscribe for 404,795 shares of the Company subject to certain vesting conditions, representing approximately 0.0672% of the issued shares of the Company, pursuant to the Company’s pre-IPO share option scheme adopted on 12 July 2010. He was interested in these shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”). As at the date hereof, Dr. Zhang has not exercised these share options.

Save as disclosed above, Dr. Zhang (i) has no other relationship with any director, senior management or substantial or controlling shareholder of the Company; (ii) has not held any directorship in other listed public companies in the last three years; and (iii) does not have any other interest in the shares, underlying shares or debentures of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, there is no other information relating to Dr. Zhang’s re-designation of director and resignation of other positions in the Company that need to be brought to the attention of the shareholders of the Company or disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Dr. Zhang has also confirmed that he has no disagreement with the Board and there is no matter that needs to be brought to the attention of the shareholders of the Company in relation to his re-designation of director and resignation of other positions in the Company.

APPOINTMENT OF CHIEF TECHNOLOGY OFFICER

The Board also announces that, following Dr. Zhang’s resignation as the chief technology officer of the Company, Dr. Patrice Malard has been appointed as the chief technology officer of the Company with effect from 25 June 2012.

Dr. Patrice Malard, aged 57, joined the Group in October 2010. He is the chief scientific officer of the Company and is mainly responsible for providing technical support and advice to the research and development of its products. He was the scientific consultant of Biostime Guangzhou from 1 March 2008 to 30 September 2010. Dr. Patrice has approximately 20 years of experience in the nutrition products industry. From October 1981 to March 1990, he worked for Gist Brocades SA as a science director. From April 1990 to June 1991, he was employed by CPIAA SA as a manager. From June 1991 to November 1994, he was the strategy and development director of the French subsidiary of Pioneer France Maïs SA. He also has worked as a director of Silab Sarl and sales and marketing director of Lallemand SAS for the period from February 1995 to October 2007. From March 2008 till now, he was

the owner of Kloarys Développement Sarl and acted as the general manager. He obtained his Ph.D. in molecular and cellular Biology from Lille University of Science and Technology in 1981.

By Order of the Board
Biostime International Holdings Limited
Luo Fei
Chairman

Hong Kong, 25 June 2012

As at the date of this announcement, the executive directors of the Company are Mr. Luo Fei and Ms. Kong Qingjuan; the non-executive directors of the Company are Dr. Zhang Wenhui, Mr. Wu Xiong, Mr. Luo Yun and Mr. Chen Fufang; and the independent non-executive directors of the Company are Dr. Ngai Wai Fung, Mr. Tan Wee Seng and Professor Xiao Baichun.